Osilodrostat Completed Phase 2 Trials for Cushing's Disease Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01331239Safety and Efficacy of LCI699 in Cushing's Disease Patients.